Celularity Inc.

NASDAQ:CELU

Biotechnology

Healthcare
$1.83 +138.53%

+$1.22 today

Market cap
$52.97M
Beta
0.54
P/E (TTM)
-0.6
EPS (TTM)
-$3.58
52W Low $0.56High $4.00

Volume 0.00M

Average 0.13M

CELU Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Celularity Inc.NASDAQ: CELU

Weighted Avg Shares · Q4 FY2025 · quarter ended Dec 2025

Weighted avg shares grows in line with its trailing trend

Q4 FY2025 weighted avg shares of 25.6M shares rose 14.5% year over year, ahead of the +13.6% change in trailing-twelve-month weighted avg shares. Sequentially, it fell 2.8% from the prior quarter. Over 3 fiscal years it compounded at +22.3% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +14.5% holds above the trailing-twelve-month pace of +13.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
25.6M-2.8% QoQ
Last fiscal yearDec 2025
25.6M+16.9% YoY
LTMDec 2025
24.87M+13.6% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+14.5%——
1 year+16.9%——
3-year CAGR+22.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
25.6M USD
Year-over-year change
+16.9%
4-year CAGR
+19.1%

Weighted Avg Shares vs competitors

How CELU compares with its peers on the latest reported figures

  • CELU's LTM Dec 2025 weighted avg shares of 24.87M shares is the 2nd highest of the 4 companies compared; the peer median is 22.96M shares.
  • Its year-over-year change of +13.6% is the 3rd highest of 4, against a peer median of +82.7%.
  • Over three fiscal years its annual growth of +22.3% compares with a peer median of +36.0%.
CELU Competitors Peer median
Weighted Avg Shares for CELU and competitors
Company Period LTM YoY 3-year CAGR
ATNMActinium Pharmaceuticals, Inc.LTM Jun 202631.26M +0.3%+8.9%
CELUCelularity Inc.LTM Dec 202524.87M +13.6%+22.3%
ANVSAnnovis Bio, Inc.LTM Mar 202622.96M +82.7%+36.0%
PYPDPolyPid Ltd.LTM Mar 202618.85M +145.8%+132.8%
Peer median (excluding CELU) 22.96M+82.7%+36.0%

Competitors are the stored peer set for CELU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue21.34M17.98M22.77M54.22M26.55M
Cost of Revenue9.65M19.67M16.02M14.99M6.36M
Gross Profit11.68M(1.69M)6.76M39.23M20.19M
Gross Margin54.8%-9.4%29.7%72.4%76.0%
Research & Development88.35M78.36M30.47M17.39M15.03M
Selling, General & Admin71.34M66.02M50.58M58.64M51.27M
Operating Expenses120.74M23.91M199.04M77.59M81.5M
Depreciation & Amortization8.82M9.44M9.32M7.92M7.3M
EBITDA(88.11M)(138.83M)(183.95M)(43.71M)(77.66M)
EBITDA Margin-413.0%-772.4%-807.8%-80.6%-292.5%
Operating Income(109.06M)(25.6M)(192.29M)(38.36M)(61.31M)
Operating Margin-511.2%-142.4%-844.4%-70.7%-230.9%
Interest Income332K365K320K331K262K
Interest Expense3.17M03.02M6.26M6.75M
Other Income / Expenses8.96M39.81M(4M)(19.53M)(30.41M)
Income Before Tax(100.1M)14.21M(196.29M)(57.89M)(91.71M)
Pre-Tax Margin-469.2%79.0%-862.0%-106.8%-345.4%
Income Tax Expense20K13K10K03K
Net Income(100.12M)14.19M(196.3M)(57.89M)(91.8M)
Net Margin-469.3%79.0%-862.0%-106.8%-345.8%
EPS (Basic)(7.87)1.01(11.02)(2.64)(3.59)
EPS (Diluted)(7.87)0.95(11.02)(2.64)(3.59)
Weighted Avg Shares12.73M13.99M17.81M21.89M25.6M
Weighted Avg Shares (Diluted)12.73M14.98M17.81M21.89M25.6M

Celularity Inc.

NASDAQ:CELU

Intrinsic Alpha fair value

Locked

Current Price

$1.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.